ATAI
Price
$4.57
Change
+$0.01 (+0.22%)
Updated
Sep 5 closing price
Capitalization
979.53M
72 days until earnings call
CRSP
Price
$54.86
Change
+$2.12 (+4.02%)
Updated
Sep 5 closing price
Capitalization
4.99B
52 days until earnings call
Interact to see
Advertisement

ATAI vs CRSP

Header iconATAI vs CRSP Comparison
Open Charts ATAI vs CRSPBanner chart's image
ATAI Life Sciences
Price$4.57
Change+$0.01 (+0.22%)
Volume$3.17M
Capitalization979.53M
CRISPR Therapeutics AG
Price$54.86
Change+$2.12 (+4.02%)
Volume$2.74M
Capitalization4.99B
ATAI vs CRSP Comparison Chart in %
Loading...
ATAI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CRSP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ATAI vs. CRSP commentary
Sep 08, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATAI is a Hold and CRSP is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 08, 2025
Stock price -- (ATAI: $4.57 vs. CRSP: $54.86)
Brand notoriety: ATAI and CRSP are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ATAI: 52% vs. CRSP: 90%
Market capitalization -- ATAI: $979.53M vs. CRSP: $4.99B
ATAI [@Biotechnology] is valued at $979.53M. CRSP’s [@Biotechnology] market capitalization is $4.99B. The market cap for tickers in the [@Biotechnology] industry ranges from $101.56B to $0. The average market capitalization across the [@Biotechnology] industry is $1.92B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ATAI’s FA Score shows that 1 FA rating(s) are green whileCRSP’s FA Score has 0 green FA rating(s).

  • ATAI’s FA Score: 1 green, 4 red.
  • CRSP’s FA Score: 0 green, 5 red.
According to our system of comparison, ATAI is a better buy in the long-term than CRSP.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ATAI’s TA Score shows that 3 TA indicator(s) are bullish while CRSP’s TA Score has 3 bullish TA indicator(s).

  • ATAI’s TA Score: 3 bullish, 5 bearish.
  • CRSP’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, CRSP is a better buy in the short-term than ATAI.

Price Growth

ATAI (@Biotechnology) experienced а -0.22% price change this week, while CRSP (@Biotechnology) price change was +5.85% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.52%. For the same industry, the average monthly price growth was +14.52%, and the average quarterly price growth was +33.01%.

Reported Earning Dates

ATAI is expected to report earnings on Nov 18, 2025.

CRSP is expected to report earnings on Oct 29, 2025.

Industries' Descriptions

@Biotechnology (+2.52% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRSP($4.99B) has a higher market cap than ATAI($980M). ATAI YTD gains are higher at: 243.609 vs. CRSP (39.380). ATAI has higher annual earnings (EBITDA): -115.96M vs. CRSP (-533.5M). CRSP has more cash in the bank: 1.72B vs. ATAI (95.9M). ATAI has less debt than CRSP: ATAI (9.22M) vs CRSP (215M). CRSP has higher revenues than ATAI: CRSP (35M) vs ATAI (2.31M).
ATAICRSPATAI / CRSP
Capitalization980M4.99B20%
EBITDA-115.96M-533.5M22%
Gain YTD243.60939.380619%
P/E RatioN/AN/A-
Revenue2.31M35M7%
Total Cash95.9M1.72B6%
Total Debt9.22M215M4%
FUNDAMENTALS RATINGS
ATAI vs CRSP: Fundamental Ratings
ATAI
CRSP
OUTLOOK RATING
1..100
2284
VALUATION
overvalued / fair valued / undervalued
1..100
72
Overvalued
64
Fair valued
PROFIT vs RISK RATING
1..100
84100
SMR RATING
1..100
9896
PRICE GROWTH RATING
1..100
3546
P/E GROWTH RATING
1..100
1479
SEASONALITY SCORE
1..100
8775

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CRSP's Valuation (64) in the Biotechnology industry is in the same range as ATAI (72) in the Miscellaneous Commercial Services industry. This means that CRSP’s stock grew similarly to ATAI’s over the last 12 months.

ATAI's Profit vs Risk Rating (84) in the Miscellaneous Commercial Services industry is in the same range as CRSP (100) in the Biotechnology industry. This means that ATAI’s stock grew similarly to CRSP’s over the last 12 months.

CRSP's SMR Rating (96) in the Biotechnology industry is in the same range as ATAI (98) in the Miscellaneous Commercial Services industry. This means that CRSP’s stock grew similarly to ATAI’s over the last 12 months.

ATAI's Price Growth Rating (35) in the Miscellaneous Commercial Services industry is in the same range as CRSP (46) in the Biotechnology industry. This means that ATAI’s stock grew similarly to CRSP’s over the last 12 months.

ATAI's P/E Growth Rating (14) in the Miscellaneous Commercial Services industry is somewhat better than the same rating for CRSP (79) in the Biotechnology industry. This means that ATAI’s stock grew somewhat faster than CRSP’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ATAICRSP
RSI
ODDS (%)
Bearish Trend 3 days ago
87%
N/A
Stochastic
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
80%
Momentum
ODDS (%)
Bullish Trend 3 days ago
81%
Bullish Trend 3 days ago
76%
MACD
ODDS (%)
Bearish Trend 3 days ago
84%
N/A
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
85%
Bullish Trend 3 days ago
77%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
81%
Bearish Trend 3 days ago
85%
Advances
ODDS (%)
Bullish Trend 3 days ago
82%
Bullish Trend 5 days ago
80%
Declines
ODDS (%)
Bearish Trend 24 days ago
85%
Bearish Trend 10 days ago
83%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
82%
N/A
Aroon
ODDS (%)
Bullish Trend 3 days ago
82%
Bearish Trend 3 days ago
85%
View a ticker or compare two or three
Interact to see
Advertisement
ATAI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CRSP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
AEPCX59.440.30
+0.51%
American Funds EUPAC C
NINLX23.460.09
+0.39%
Neuberger Berman Intrinsic Value I
GSRFX12.91-0.01
-0.08%
Goldman Sachs Rising Dividend Gr R6
ACGLX23.05-0.12
-0.52%
Invesco Growth and Income R
RMBJX26.47-0.16
-0.60%
RMB C

ATAI and

Correlation & Price change

A.I.dvisor indicates that over the last year, ATAI has been loosely correlated with MNMD. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if ATAI jumps, then MNMD could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ATAI
1D Price
Change %
ATAI100%
+0.22%
MNMD - ATAI
51%
Loosely correlated
-0.11%
RXRX - ATAI
42%
Loosely correlated
+1.99%
CYBN - ATAI
41%
Loosely correlated
+12.54%
SYRE - ATAI
40%
Loosely correlated
+0.06%
CRSP - ATAI
39%
Loosely correlated
+4.02%
More

CRSP and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRSP has been closely correlated with RXRX. These tickers have moved in lockstep 68% of the time. This A.I.-generated data suggests there is a high statistical probability that if CRSP jumps, then RXRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRSP
1D Price
Change %
CRSP100%
+4.02%
RXRX - CRSP
68%
Closely correlated
+1.99%
BEAM - CRSP
66%
Loosely correlated
+12.62%
NTLA - CRSP
64%
Loosely correlated
+3.79%
CRBU - CRSP
59%
Loosely correlated
+1.08%
ABCL - CRSP
58%
Loosely correlated
+1.44%
More